The upcoming earnings report for Ionis Pharmaceuticals, Inc. is set for Tuesday, April 28th, with a consensus estimated EPS of -0.86.
Ionis Pharmaceuticals, Inc. currently trades at $71.91, experiencing a price decrease of -32.3 cents (-0.447%) from the previous close. The trading volume stands at $530,638, representing a 25.3% increase relative to the average.
The asset has shown a three-day streak of decline, with a -3.91% decrease from the price at the start of the streak at $74.83.
In the latest quarterly earnings report on Tuesday, February 24th, Ionis Pharmaceuticals, Inc. reported a consensus estimated EPS of -1.23667 and an estimated revenue of $156 million.
Morgan Stanley's recent analysis on April 21st maintained Ionis Pharmaceuticals, Inc.'s grade at "Overweight," with a price of $74.87 and a recommendation to "hold."
The company's cash flow depicts a net change in cash of $33.92 million, with operating cash flow at $-137.71 million and debt repayment at $-483.36 million.
Ionis Pharmaceuticals, Inc. reported a net income of $-229 million, resulting in an EPS of -$1.41, with revenues totaling $203 million.
Key ratios include a quick ratio of 3.81, gross profit margin of 96.06%, and a price-to-book ratio of 26.2.
The balance sheet shows total assets of $3.52 billion, including $372.26 million in cash and cash equivalents and $2.31 billion in short-term investments.
This real-time financial report offers insights into Ionis Pharmaceuticals, Inc.'s current performance and financial health as the market close approaches.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.